Showing results (4101-4110 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|November 5, 2013
Novel therapeutic strategies in major depression: focus on RNAi and ketamineAnalia Bortolozzi, Pau Celada, Francesc ArtigasCurrent Pharmaceutical Design|November 5, 2013
Population based Helicobacter pylori screening and eradication: advances versus side effectsBojan TepesCurrent Pharmaceutical Design|August 28, 2013
Synergistic effect of inhibitors of MMPs and ROS-dependent modifications of contractile proteins on protection hearts subjected to oxidative stressGrzegorz SawickiCurrent Pharmaceutical Design|August 28, 2013
Effects of a selective histamine H₄R antagonist on inflammation in a model of carrageenan-induced pleurisy in the ratA Pini, T Somma, G Formicola, et al.Current Pharmaceutical Design|August 28, 2013
Targeted gene deletion of prolyl hydroxylase domain protein 3 triggers angiogenesis and preserves cardiac function by stabilizing hypoxia inducible factor 1 alpha following myocardial infarctionBabatunde Oriowo, Mahesh Thirunavukkarasu, Vaithinathan Selvaraju, et al.Current Pharmaceutical Design|September 13, 2013
Bridge between neuroimmunity and traumatic brain injuryMatthew L Kelso, Howard E GendelmanCurrent Pharmaceutical Design|September 13, 2013
Neurobiological influences on recovery from traumatic brain injury: the role of genetic polymorphismsStarla M Weaver, Jaclyn N PortelliCurrent Pharmaceutical Design|September 13, 2013
Disorders of consciousness and pharmaceuticals that act on oxygen based amino acid and monoamine neurotransmitter pathways of the brainRalf ClaussCurrent Pharmaceutical Design|September 13, 2013
True or false? Activations of language-related areas in patients with disorders of consciousnessBoris Kotchoubey, Tao Yu, Friedemann Mueller, et al.Current Pharmaceutical Design|September 13, 2013
Ethical aspects of vegetative and minimally conscious statesPierre Mallia, Raffaele Daniele, Simona Sacco, et al.Pageof 1,008